



MICHIGAN DEPARTMENT OF HEALTH AND HUMAN SERVICES
Medical Services Administration
Pharmacy Management Division

Summary of Pharmacy Liaison Meeting on December 8th, 2022

Introductions & Budget Update: No budget update to provide

Final Policies Issued

MMP 22-38: *Reinstatement of Provider Enrollment Requirements*

November 2022: MDHHS will begin notifying providers of their rescheduled revalidation dates. Revalidation dates will be assigned on a rolling basis beginning with providers who have had the longest revalidation pause. Providers may also view their rescheduled revalidation date in CHAMPS. Enrollment application fees do not apply to pharmacists

December 1, 2022: The provider enrollment requirements that will be reinstated include site visits and fingerprint-based criminal background checks associated with providers in the high-risk level category.

MMP 22-29: *COVID-19 Response: Authorization of U.S. Food & Drug Administration (FDA) Emergency Use Authorization (EUA) of Pharmacists to Prescribe COVID-19 Oral Therapeutics Effective July 6, 2022*, in accordance with the 9th Amendment of the Public Readiness and Emergency Preparedness (PREP) Act, pharmacists prescribing and dispensing of COVID-19 Oral Therapeutics is allowed for Medicaid coverage.

Proposed Policy

2245 – Practitioner: Updates to the Coverage of Routine Patient Costs for Items and Services Associated with Participation in a Qualifying Clinical Trial

Effective January 1, 2023: Pharmacy items and services that require a Prior Authorization (PA) where provided in connection with a beneficiary's participation in a qualified clinical trial will now require submission of BPHASA 2210. This form is required by Section 210 of the Consolidated Appropriations Act of 2021, and attests that the pharmacy items and services are in connection to the beneficiary's participation in a qualified clinical trial. The forms section within the Medicaid Provider Manual will be updated to include a link to this form, and the form itself will be issued with the final policy bulletin. The form will also be provided on the Prior Authorization Forms section of <https://michigan.magellanrx.com>

Provider Letters

L 22-55: *Pharmacist Ordering of Self-Administered Hormonal Contraceptives*

Note: This coverage clarification has now been finalized and issued to all providers.

In response to [Executive Directive 2022-5](#), the Michigan Department of Licensing and Regulatory Affairs (LARA) issued an [Interpretive Statement](#) of the Public Health Code effectively allowing a physician licensed in Michigan to delegate limited prescriptive authority to a

Michigan-licensed pharmacist to prescribe self-administered, hormonal contraceptives in accordance with described requirements.

For a qualified pharmacist to generate a prescription for hormonal birth control, a Delegation Agreement is required with a physician. **Pharmacies use the Delegating Physician's NPI as the prescriber.** The interpretive statement, delegation agreement template, and frequently asked questions can be found on LARA's website: <https://michigan.gov/lara/>>> Bureau of Professional Licensing >> Health Licensing >> Pharmacy >> Delegation of Prescriptive Authority to Pharmacists. MDHHS Bulletin [HASA 22-12](#) applies to this provision as well, allowing for up to a 12-month supply of prescribed contraceptives. Current coverage for self-administered hormonal contraceptive drug products, including oral, vaginal ring, and contraceptive hormonal patches, can be located on the Michigan Pharmaceutical Product List (MPPL) found at <https://michigan.magellanrx.com> >> Provider >> Documents >> Fee For Service Drug Coverage >> MPPL and Coverage Information.

If a beneficiary does not have a hormonal contraception prescription and is requesting one, a pharmacy provider without a Delegation Agreement should work with the beneficiary's physician to obtain a prescription.

[L-letter 22-54: Plan First! New Family Planning Eligibility Group](#)

MDHHS establishing a new Family Planning Medicaid Group (Plan First!) which will provide access to family planning services for Michiganders who have incomes below 200% of the federal poverty level. Claims Team is working through identifying what benefits will exist in this new plan for CHAMPS coding purposes.

Departmental Updates

A 60-day advanced notice of Public Health Emergency (PHE) termination from CMS to the States has not been sent, so States are assuming that the PHE will not be terminating prior to April of 2023.

Dispensing Fee Limit Increase for Opioid Use Disorder Treatments is now in place at point of sale to accommodate prescriptions in this class that might be written for weekly dispensing. HIC3 = H3W, Opioid Withdrawal Agents, Opioid Type.

Policy Reminders

Emergency Services Only (ESO) Benefit: MDHHS encourages pharmacy providers to review both the [Medicaid Provider Manual](#) and the [Pharmacy Claims Processing Manual](#) to remain familiar with the coverage parameters of the ESO benefit, the expectations of providers providing items or services for ESO beneficiaries, and the claims submission & documentation requirements.

Federal Medicaid regulations define an emergency medical condition as a *sudden onset of a physical or mental condition which causes acute symptoms*, including severe pain, where the absence of immediate medical attention could reasonably be expected to:

- a. Place the person's health in serious jeopardy, or

- b. Cause serious impairment to bodily functions, or
- c. Cause serious dysfunction of any bodily organ or part

Reminder that by submitting level of service = '3' pharmacists are attesting the service is related to an emergent condition.

Providers should be aware that the Medicaid Provider Manual also states that other insurance information is not displayed on the beneficiary's 'MiHealth' card. Pharmacies are responsible for verifying eligibility and other insurance information by using the Community Health Automated Medicaid Processing System (CHAMPS). ESO coverage is identified as "MA-ESO" eligibility type. Trish Bouck added that an NCPDP Eligibility (E1) transaction can also be submitted to SureScripts for eligibility verification purposes if utilized by pharmacies.

Partial Fills: Policy Allowing Partial Fills MSA 08-25: Effective for dates of service on or after July 1, 2008, a pharmacy provider will have two options in billing and being reimbursed for partially filled prescription drug(s):

- a. When there is a shortage in inventory or;
- b. When a beneficiary receives small quantities of prescribed drugs (including controlled substances) due to terminal illness or residing in a nursing facility.

Condom Supply Limits: 12 condoms per fill, not more than 36 per 30 days

Single PDL and Brand Over Generic: 12/1/2022

Brand over Generic List can be found here:

<https://michigan.magellanrx.com/provider/documents/>

Quarterly, the MCO Common Formulary workgroup provides recommendations on Single PDL coverage for P&T Workgroup consideration. The P&T Committee makes clinical recommendations for both the Michigan Pharmaceutical Product List (MPPL) and the subset of drugs on the Single PDL

New quarterly web posting 'Summary of PDL changes' to better inform prescribers and pharmacies can be found here: <https://michigan.magellanrx.com/provider/> >> "Recent Changes – MI Single Preferred Drug List (Single PDL)"

The next quarterly PDL updates will take effect February 1, 2023

Web Announcements: <https://michigan.magellanrx.com/provider/notifications>

Vaccine Administration Fee Increase per SPA approval is now in place.

Open Discussion:

Eric Nordan asked who has historical information regarding the change to ESO in 10/17? Was that a FOIA request or a meeting with someone at Magellan? Trish Bouck responded that she believes it was based on internal discussions resulting from feedback from pharmacy liaisons and working with NCPDP to better ensure pharmacy providers were aware of ESO coverage limitations.

Resources

1. MDHHS Policy Bulletins:
 - www.michigan.gov/medicaidproviders > Policy, Letters & Forms
2. Web Announcements: <https://michigan.magellanrx.com>
3. Magellan Technical Call Center Phone: 877-624-5204
4. <https://www.CDC.gov/Coronavirus> or <https://www.michigan.gov/Coronavirus>
5. MDHHS Pharmacy Services Contact: MDHHSPharmacyServices@Michigan.gov
6. Laws
 - [Michigan Public Health Code – general](#)
 - [Michigan Public Health Code – pharmacy](#)
7. Rules
 - [Michigan Administrative Code – pharmacy rules](#)

2023 Pharmacy Liaison Meeting Dates: Tentative – as follows P&T and DUR meeting schedule. These will remain on Thursday afternoons 2:30pm – 4:00pm and be hosted on Microsoft Teams.

- March 9, 2023
- June 8, 2023
- September 7, 2023
- December 7, 2023